Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term follow-up from the OMNIVORE trial: response-adaptive nivolumab and ipilimumab in advanced renal cell carcinoma.

Journal for immunotherapy of cancerยท2026
Same author

Outcomes for females versus males treated with eribulin mesylate for advanced urothelial carcinoma.

Current problems in cancerยท2026
Same author

Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study.

Clinical cancer research : an official journal of the American Association for Cancer Researchยท2026
Same author

Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4.

Journal of clinical oncology : official journal of the American Society of Clinical Oncologyยท2026
Same author

The comeback of orchiectomy in advanced prostate cancer- is that feasible?

Urologic oncologyยท2025
Same author

Phase 3 Trial of Dose-Escalated Radiation Therapy and Standard Androgen Deprivation Therapy Versus Dose-Escalated Radiation Therapy and Enhanced Androgen Deprivation Therapy With Orteronel for Men With High-Risk Prostate Cancer (NRG/RTOG 1115).

International journal of radiation oncology, biology, physicsยท2025

Related Experiment Video

Updated: May 8, 2026

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Predictive markers in advanced renal cell carcinoma.

M Dror Michaelson1, Walter M Stadler

  • 1Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA. dmichaelson1@partners.org

Seminars in Oncology
|August 27, 2013
PubMed
Summary
This summary is machine-generated.

Identifying predictive biomarkers is crucial for advanced renal cell carcinoma (RCC) treatment. These markers, including clinical, toxicity, serum, tissue, and imaging, help personalize therapy for better patient outcomes.

More Related Videos

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Related Experiment Videos

Last Updated: May 8, 2026

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Area of Science:

  • Oncology
  • Biomarker Research

Background:

  • Advanced renal cell carcinoma (RCC) has numerous treatment options.
  • Predictive markers are essential for tailoring therapy to individual patients.

Purpose of the Study:

  • To review various types of predictive biomarkers for advanced RCC.
  • To highlight the potential of different marker categories in predicting treatment response.

Main Methods:

  • Review of existing literature on predictive markers in advanced RCC.
  • Categorization of biomarkers into clinical, toxicity-based, serum, tissue, and radiologic types.

Main Results:

  • Clinical factors have limited predictive value for therapy response.
  • Hypertension correlates with response to angiogenesis-targeted therapy.
  • Serum lactate dehydrogenase (LDH), cytokines, and functional imaging (PET, DCE-MRI, DCE-US) show promise.

Conclusions:

  • Developing predictive biomarkers is key for personalized treatment strategies in advanced RCC.
  • Functional imaging modalities warrant further investigation for predicting treatment efficacy.